Openbookopenbook
Equity
Nuformix plc(NFX)
GBX --+0.00%
Reward29Low
Risk64Medium-High
📊75%Data
Revenue down 74% YoY
NFX
+0.0 · +0.00%
GBX · LSE
Nuformix plc | Healthcare
Earnings Deterioration
Market Cap:4.43M
ℹ️
Reward Rating
29
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
64
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on NFX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 10p.

What is Nuformix plc?

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

NFX · Verdict

Limited reward · elevated risk

NFX's standout is balance sheet; cash flow and profitability weigh on the picture.

Based on 88% data coverage

NFX · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet67/100

    Current ratio 0.52

Watchouts 4

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -89% return on equity

  • Growth18/100

    Earnings -5.0% CAGR

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Nuformix plc?

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 4.43M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap4.43M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.555
52 Week Low0.0695
Last AnnualMarch
IPO DateN/A
IncorporatedUK
Shares Outstanding2B
No. of Employees3
IndustryBiotechnology
ExchangeLSE
Beta1.406
CurrencyGBX · Reports in GBP
Websitewww.nuformix.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.